The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder
Open accessAbstract
The effectiveness of antimuscarinic agents in the treatment of the overactive bladder (OAB) syndrome is thought to arise through blockade of bladder muscarinic receptors located on detrusor smooth muscle cells, as well as on nondetrusor structures. Muscarinic M 3 receptors are primarily responsible for detrusor contraction. Limited evidence exists to suggest that M 2 receptors may have a role in mediating indirect contractions and/or inhibition of detrusor relaxation. In addition, there is evidence that muscarinic receptors located in the urothelium/suburothelium and on afferent nerves may contribute to the pathophysiology of OAB. Blockade of these receptors may also contribute to the clinical efficacy of antimuscarinic agents. Although the role of muscarinic receptors in the bladder, other than M 3 receptors, remains unclear, their role in other body systems is becoming increasingly well established, with emerging evidence supporting a wide range of diverse functions. Blockade of these functions by muscarinic receptor antagonists can lead to similarly diverse adverse effects associated with antimuscarinic treatment, with the range of effects observed varying according to the different receptor subtypes affected. This review explores the evolving understanding of muscarinic receptor functions throughout the body, with particular focus on the bladder, gastrointestinal tract, eye, heart, brain and salivary glands, and the implications for drugs used to treat OAB. The key factors that might determine the ideal antimuscarinic drug for treatment of OAB are also discussed. Further research is needed to show whether the M 3 selective receptor antagonists have any advantage over less selective drugs, in leading to fewer adverse events. British Journal of Pharmacology(2006)148, 565–578. doi:10.1038/sj.bjp.0706780
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., van Kerrebroeck, P., Victor, A., & Wein, A. (2002) · Neurourology and Urodynamics · doi:10.1002/nau.10052 · Cited by 8,296
Self-citationA systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors
Caulfield, M. P., & Birdsall, N. J. M. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01362-0 · Cited by 1,474
Hulme, E. C., Birdsall, N. J. M., & Buckley, N. J. (1990) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.30.040190.003221 · Cited by 1,338
Muscarinic Receptors—Characterization, coupling and function
Caulfield, M. P. (1993) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(93)90027-b · Cited by 1,277
Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550160091022 · Cited by 692
A neurologic basis for the overactive bladder
de Groat, W. C. (1997) · Urology · doi:10.1016/s0090-4295(97)00587-6 · Cited by 596
Self-citationSelective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice
Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S. L., Rahnama, N. P., Nathanson, N. M., & Silva, A. J. (2003) · Nature Neuroscience · doi:10.1038/nn992 · Cited by 544
Self-citation
Cited by
Chapple, C. R., Khullar, V., Gabriel, Z., Muston, D., Bitoun, C. E., & Weinstein, D. (2008) · European Urology · doi:10.1016/j.eururo.2008.06.047 · Cited by 769
Self-citationMuscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Wess, J., Eglen, R. M., & Gautam, D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2379 · Cited by 637
Gender and incidence of dementia in the Framingham Heart Study from mid‐adult life
Chêne, G., Beiser, A., Au, R., Preis, S. R., Wolf, P. A., Dufouil, C., & Seshadri, S. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.005 · Cited by 499
Chughtai, B., Forde, J. C., Thomas, D. D. M., Laor, L., Hossack, T., Woo, H. H., Te, A. E., & Kaplan, S. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.31 · Cited by 462
Bile Acids Signal via TGR5 to Activate Intestinal Stem Cells and Epithelial Regeneration
Sorrentino, G., Perino, A., Yildiz, E., El Alam, G., Bou Sleiman, M., Gioiello, A., Pellicciari, R., & Schoonjans, K. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.067 · Cited by 399
Mechanisms of Disease: involvement of the urothelium in bladder dysfunction
Birder, L. A., & de Groat, W. C. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0672 · Cited by 364
Self-citationPeter, J. V., Sudarsan, T., & Moran, J. (2014) · Indian Journal of Critical Care Medicine · doi:10.4103/0972-5229.144017 · Cited by 286
Nimgampalle, M., Chakravarthy, H., Sharma, S., Shree, S., Bhat, A. R., Pradeepkiran, J. A., & Devanathan, V. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101994 · Cited by 207
The biosynthesis, signaling, and neurological functions of bile acids
Kiriyama, Y., & Nochi, H. (2019) · Biomolecules · doi:10.3390/biom9060232 · Cited by 204
Anticholinergics: theoretical and clinical overview
Nishtala, P. S., Salahudeen, M. S., & Hilmer, S. N. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1165664 · Cited by 167
Kay, G. G., & Ebinger, U. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01849.x · Cited by 141
Self-citationBladder, Bowel, and Sexual Dysfunction in Parkinson's Disease
Sakakibara, R., Kishi, M., Ogawa, E., Tateno, F., Uchiyama, T., Yamamoto, T., & Yamanishi, T. (2011) · Parkinson's Disease · doi:10.4061/2011/924605 · Cited by 118
Bile acids as key modulators of the brain-Gut-Microbiota axis in alzheimer’s disease
Mulak, A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210608 · Cited by 114
“TCA, GDCA, and TDCA activate muscarinic acetylcholine receptors (M2 and M3) that are known to play an important role in cognitive function, memory, and learning [65].”
BackgroundAnticholinergic Drug Burden in Older People's Brain - How well is it Measured?
Kersten, H., & Wyller, T. B. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12140 · Cited by 112
Ferreira, J. P. S., Albuquerque, H. M. T., Cardoso, S. M., Silva, A. M. S., & Silva, V. L. M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113492 · Cited by 96
Soukup, O., Winder, M., Killi, U. K., Wsol, V., Jun, D., Kuca, K., & Tobin, G. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160607212615 · Cited by 34
Jia, X., Chen, Q., Zhang, Y., & Asakawa, T. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1296713 · Cited by 22
Metadata
- Authors
- Abrams, P., Andersson, K., Buccafusco, J. J., Chapple, C., de Groat, W. C., Fryer, A. D., Kay, G., Laties, A., Nathanson, N. M., Pasricha, P. J., & Wein, A. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2006-07
- Volume
- 148
- Issue
- 5
- Pages
- 565-578
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2105391780
- Cited by
- 632
- References
- 69
- FWCI
- 30.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.